Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp. develops and commercializes immunosequencing technologies used to decode the adaptive immune system for clinical diagnostics and therapeutic discovery. A core component of its business involves partnering with pharmaceutical companies to discover and develop novel immunotherapies, which are subject to regulatory approval processes that typically require animal testing.

The company’s business model is built on collaborations with major pharmaceutical firms to translate immune receptor data into drug candidates. For example, Adaptive has entered into significant, non-exclusive licensing agreements with Pfizer, worth up to $890 million, focused on discovering T-cell receptor therapeutics for oncology and autoimmune diseases. The development pathway for such biologic therapies, from target discovery through preclinical and clinical stages, routinely involves animal research to establish safety and efficacy, as mandated by global regulatory bodies like the U.S. Food and Drug Administration.

While Adaptive’s primary role is as a technology and discovery partner, its commercial success is directly tied to the progression of partnered therapeutic programs through the drug development pipeline, a process that commissions and funds animal testing as a standard requirement. The company’s affiliations and collaborations place it within the network of contract research organizations and biopharma entities that conduct animal research.